Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVING Study: Naldemedine vs Magnesium for Opioid-Induced Constipation and Nausea in Cancer
jRCTs031250525Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in cancer pain, opioid-induced constipation (OIC) and Opioid-induced nausea and vomiting (OINV) comparing Naldemedine arm with Magnesium oxide arm (2 arms). Primary endpoints: Primary: Bowel Movement Quality of Life and Primary: Presence or absence of opioid-induced nausea and vomiting (OINV). Started May 2026; status: recruiting.
02
Drugs
naldemedinemagnesium oxide
03
Conditions
cancer painopioid-induced constipation (OIC)Opioid-induced nausea and vomiting (OINV)
Beyond the preview
Go deeper on jRCTs031250525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250525.